Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma

References

• Grillo-Lopez AJ, White CA, Varns C et al Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Sernin. Oncol 26(5 Suppl. 14), 66–73 (1999).
   Google Scholar
• •Historically important publication on this significant achievement.
   Google Scholar
• Grillo-Lopez AJ. Rituximab: an insider's historical perspective. Semin. Oncol 27, 6(12 Suppl), 9–16 (2000).
   Google Scholar
• •Interesting perspective by an insider providing information on how this antibody was developed.
   Google Scholar
• Coiffier B, Lepage E, Briére J et al Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large B-cell lymphoma. N Engl. Merl 346(4), 235–242 (2002).
   Google Scholar
• ••This paper is obligatory reading foranyone involved in the treatment of NHL as it marks the first time that a combination was proven superior to CHOP
   Google Scholar
• Grillo-López AJ. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Exper t Rev. Anticancer Ther. 2(3), 323–329 (2002).
   Google Scholar
• ••Provides his opinion on how NHL shouldbe treated in the age of antibodies.
   Google Scholar
• Grillo-López AJ. Curative therapies for NHL: a question of time Editorial in monoclonal antibodies in the treatment of hematologic malignancies. C1.117: Pharm. Biotechnol 2(4), (2001).
   Google Scholar
• •We should all be concerned at the slow pace of the development of new antilymphoma agents and combination therapies.
   Google Scholar
• Grillo-López AJ. Radioimmunotherapy with 90-yttrium Zevalin for indolent or aggressive non-Hodgkin's lymphomas. Haematologica 86, 65–69 (2001).
   Google Scholar
• •An early review of Zevalin approval data.
   Google Scholar
• Grillo-LOpez AJ, Chinn P, Morena R et al. Phase I study of IDEC-Y2B8: 90-yttrium labeled antiCD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma. B/ooc/86(10), 55a (1995) (Abstract 207).
   Google Scholar
• •The first reported Zevalin trial.
   Google Scholar
• Kreitman RJ. Toxin labeled monoclonal antibodies. Curr Phatm. Biotechnol 2(4), 313–325 (2001).
   Google Scholar
• Meredith RF, Knox SJ. Radioimmunotherapy of B-cell NHL. Cutr Phann Biotechnol 2(4), 327–339 (2001).
   PubMedGoogle Scholar
• Grillo-Lopez AJ. Monoclonal antibody therapy for B-cell lymphoma. Int. J. Hematol 76(5), (2002).
   Web of Science ®Google Scholar
• •An up-to-date review of this area.
   Google Scholar
• Grillo-Lopez AJ, Dallaire BK, McClure A et al Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma. Cur Pharm. Biotechnol 2, 301–311 (2001).
   PubMedGoogle Scholar
• Press O, Early J, Badger C et al Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD 37)antibody. J. Gun. Oncol 7(8), 1027–1038 (1989).
   Google Scholar
• Parker BA, Vassos AB, Halpern SE et al Radioimmunotherapy of human B-cell lymphoma with 90-Y-conjugated anti-idiotype monoclonal antibody. Cancer Res. 50, 1022s-1028s (1999).
   Google Scholar
• Grillo-Lopez AJ, Chinn P, Morena R, Varns C, Parker E, Solinger AM. Phase I study of IDEC-Y2B8: 90-yttrium labeled antiCD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma. Blood 86(10), 55a (1995) (Abstract 207).
   Google Scholar
• Knox SJ, Cons ML, Trisler K et al. Yttrium-90-labeled antiCD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 2,457-470 (1996).
   Google Scholar
• ••Report on the first Phase I study withZevalin.
   Google Scholar
• White CA, Larocca A, Grillo-LOpez AJ. AntiCD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma. Pharm. Sc]. Tech. Today2(3), 95–101 (1999).
   Google Scholar
• Wiseman GA, White CA, Witzig TE et al Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 9°Y-labeled antiCD20 monoclonal antibody. Clin. Cancer Res. 5(10 Suppl.), 3281s-3286s (1999).
   Google Scholar
• Witzig TE, White CA, Wiseman GA et al Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J. Clin. Oncol 17(12), 3793–3803 (1999).
   Google Scholar
• ••Report on the Phase HI trial withZevalin.
   Google Scholar
• White CA, Berlfein JR, Grillo-LOpez AJ. Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphoma. CL117: Pharm. Biotechnol 1,303–312 (2000).
   Google Scholar
• Wiseman G, White CA, Stabin M et al Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur. J. Nucl. Merl 27,766–777 (2000).
   Google Scholar
• White CA, Weaver RL, Grillo-LOpez AJ. Antibody-targeted immunotherapy for treatment of malignancy. Ann. Rev Merl 52,125–145 (2001).
   Google Scholar
• Gordon L, Witzig TE, Wiseman GA et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin. Oncol 291(2 Suppl), 87–92 (2002).
   Google Scholar
• Witzig TE, Gordon LI, Cabanillas F et al Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkiris lymphoma. J. Glitz Once]. 20(10), 2453–2463 (2002).
   Google Scholar
• ••A must for anyone involved in the use ofZevalin as it describes the Phase III randomized study.
   Google Scholar
• Cheson BD, Homing SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J. Clin. Oncol. 17(4), 1244–1253 (1999).
   Google Scholar
• ••Important reading for anyone involved inthe treatment of NHL patients.
   Google Scholar
• Grillo-Lopez AJ, Cheson BD, Horning SJ et al Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. Ann. Onto]. 11,399–408 (2000).
   PubMed Web of Science ®Google Scholar
• •Important reading for anyone involved in the treatment of NHL patients.
   Google Scholar
• Grillo-Lopez AJ. A model for the breadth and depth of clinical activity observed with rituximab and Zevalin in NHL patients. B/ooc/100(11), (2002) .
   Google Scholar
• Shipp MA, Ambinder RF, Zelenetz AD. NCCN preliminary non-Hodgkin's lymphoma practice guidelines. Oncology 11(11A), 281–346 (1997).
   Google Scholar
• NCCN Practice Guidelines in Oncology, Non-Hodgkin's Lymphoma. Version 1 (2001).
   Google Scholar
• Wiseman GA, Gordon LI, Multani PS et al Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a Phase II multicenter trial. Blood 99,4336–4342 (2002).
   PubMed Web of Science ®Google Scholar
• Witzig TE, Flinn IW, Gordon LI et al. Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma. J. Clin. 017C01 20, 3262–3269 (2002).
   Google Scholar